What is Marksans Pharma Ltd. Quarterly Revenue?

Marksans Pharma Ltd. Quarterly Revenue Marksans Pharma Jun-2026 Quarterly Revenue is Rs 339 Cr which is growth of 5.3% YoY.

What is Marksans Pharma Ltd. Quarterly Net Profit?

Marksans Pharma Ltd. Quarterly Net Profit Marksans Pharma Jun-2026 Quarterly Net Profit is Rs 69 Cr which is growth of 43.7% YoY.

What is Marksans Pharma Ltd. Annual Revenue?

Marksans Pharma Ltd. Annual Revenue Marksans Pharma Mar-2026 Annual Revenue is Rs 1,445 Cr which is growth of 16.1% YoY.

What is Marksans Pharma Ltd. Annual Net Profit?

Marksans Pharma Ltd. Annual Net Profit Marksans Pharma Mar-2026 Annual Net Profit is Rs 301 Cr which is growth of 59.7% YoY.

What is Marksans Pharma Ltd. Total Shareholders Fund?

Marksans Pharma Ltd. Total Shareholders Fund Marksans Pharma Mar-2026 Total Shareholders Fund is Rs 1,652 Cr which is growth of 19.4% YoY.

What is Marksans Pharma Ltd. Total Assets?

Marksans Pharma Ltd. Total Assets Marksans Pharma Mar-2026 Total Assets is Rs 1,994 Cr which is growth of 13.6% YoY.

What is Marksans Pharma Ltd. Book Value Per Share?

Marksans Pharma Ltd. Book Value Per Share Marksans Pharma Mar-2026 Book Value Per Share is 36 Rs which is growth of 19.4% YoY.

What is Marksans Pharma Ltd. ROE?

Marksans Pharma Ltd. ROE Marksans Pharma Mar-2026 ROE is 18% which is growth of 4.6% YoY.

What is Marksans Pharma Ltd. Cash From Operating Activity?

Marksans Pharma Ltd. Cash From Operating Activity Marksans Pharma Mar-2026 Cash From Operating Activity is Rs 211 Cr which is growth of 580.5% YoY.

What is Marksans Pharma Ltd. Net Cash Flow?

Marksans Pharma Ltd. Net Cash Flow Marksans Pharma Mar-2026 Net Cash Flow is Rs 32 Cr which is growth of 72.1% YoY.

Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404

Mid-range Performer

Download real time

-5.00(-1.61%)

97.42% Gain from 52W Low

601.6K

NSE+BSE Volume

NSE 19 Oct, 2026 1:55 PM (IST)

Portfolio

Alert

My Notes

Marksans Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Marksans Pharma share price target, revenues, EPS, net income and more

Marksans Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Marksans Pharma Jun-2026 Quarterly Revenue is Rs 339 Cr which is growth of 5.3% YoY.
POSITIVE
Quarterly Net Profit Marksans Pharma Jun-2026 Quarterly Net Profit is Rs 69 Cr which is growth of 43.7% YoY.

Marksans Pharma Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	338.7	389.1	355.6	378.6	321.7	307.2	334.4	340	262.7	237.4	242.7	220.6	214.7
SR_Q Operating Rev.	321.2	361.6	339.7	320.4	319.7	299.4	311.9	308.6	254.5	225.2	241.4	204.7	182
OI_Q Other Income	17.5	27.5	15.9	58.2	2	7.8	22.5	31.4	8.2	12.2	1.3	15.9	32.6
OEXPNS_Q Operating Exp.	239.1	255.6	264.3	248.4	249.7	248.8	251.9	256.4	213.3	191.3	199.4	167.4	155.3
OEXPNS_Q Operating Exp.	239.1	255.6	264.3	248.4	249.7	248.8	251.9	256.4	213.3	191.3	199.4	167.4	155.3
OP_Q Operating Profit	82.1	106	75.4	72.1	70.1	50.6	59.9	52.3	41.3	33.9	42	37.3	26.8
OPMPCT_Q Operating Profit Margin %	25.56%	29.31%	22.21%	22.49%	21.91%	16.89%	19.22%	16.94%	16.21%	15.06%	17.39%	18.22%	14.70%
DEP_Q Depr.	8.8	8.8	8.8	8.5	8.2	8.2	7.4	7	6.8	7.5	8.4	8.5	4.7
INT_Q Interest	0.3	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.3
PBT_Q Profit Before Tax	90.5	124.4	82.1	121.5	63.6	49.9	74.7	76.3	42.3	38.4	34.6	44.5	54.4
TAX_Q Tax	21.4	32.4	21.2	21.7	15.5	12.3	19.3	13.1	10.3	5.4	9.3	13.2	10.2
NP_Q Net Profit	69	91.9	60.9	99.8	48.1	37.6	55.5	63.2	32	33	25.3	31.3	44.2
EPS_adj_Q EPS Adj. latest	1.5	2	1.3	2.2	1.1	0.8	1.2	1.4	0.7	0.7	0.6	0.7	1
NP_TTM Net profit TTM	321.7	300.7	246.4	240.9	204.3	188.3	183.7	153.5	121.6	133.8	118.6	118.9	127.9
EPS_TTM Basic EPS TTM	7.1	6.6	5.4	5.3	4.5	4.2	4.1	3.4	2.7	3	2.6	2.6	2.8
earnings_transcripts Earnings Transcripts
ai_summary AI Summary
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Marksans Pharma competitor comparison and performance snapshot within industry

Marksans Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Marksans Pharma Mar-2026 Annual Revenue is Rs 1,445 Cr which is growth of 16.1% YoY.
POSITIVE
Annual Net Profit Marksans Pharma Mar-2026 Annual Net Profit is Rs 301 Cr which is growth of 59.7% YoY.

Marksans Pharma Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	26.4%	18%	1,461.9	1,445	1,244.2	915.4	715.7	700.5	630.7	433.6	432.1	302.1	222.8	366.8
TotalOperatingRevenues_A Operating Rev. Ann.	27%	17.5%	1,342.9	1,341.5	1,174.4	853.3	655.2	658.3	599.6	433.4	424.2	294.7	215.8	358.1
OI_A Other Income Ann.	19.6%	27.1%	119	103.5	69.8	62.1	60.5	42.3	31.2	0.2	7.9	7.4	7	8.7
OEXPNS_A Operating Exp. Ann.	21.8%	15.9%	1,007.3	1,017.9	970.3	713.3	563.3	544.6	485.8	361.9	360.8	265.5	191.4	254.2
OEXPNS_A Operating Exp. Ann.	21.8%	15.9%	1,007.3	1,017.9	970.3	713.3	563.3	544.6	485.8	361.9	360.8	265.5	191.4	254.2
OP_A Operating Profit Ann.	52.1%	23.3%	335.6	323.6	204.1	139.9	91.9	113.7	113.7	71.5	63.3	29.2	24.5	103.9
OPMPCT_A OPM Ann. %	20.4%	4.4%		22.39%	16.40%	15.29%	12.84%	16.23%	18.03%	16.49%	14.66%	9.65%	10.99%	28.32%
TotalExpenses_A Total Exp. Ann. ⌄	21.8%	15.8%		1,053.5	1,001	743.5	583.7	566	506.4	380.9	376.1	285.4	210.8	275.2
OtherExpenses_A Other Exp. Ann.	24.4%	18.4%	209.6	217.2	228.7	157.2	112.8	106.5	93.3	70.4	78.2	50.3	39.2	49.9
EmployeeBenefitExpenses_A Employee Exp. Ann.	29.6%	17.4%	125.9	122	101.7	77.2	56.1	60.5	54.6	48.5	46.3	45.9	39.8	26.1
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	41%	24.1%		427.1	273.9	202	152.4	156	144.9	71.7	71.3	36.6	31.4	112.6
EBIDTPCT_A EBITDA Ann. margin %	11.6%	5.2%		29.56%	22.01%	22.07%	21.29%	22.26%	22.97%	16.53%	16.49%	12.11%	14.11%	30.69%
INT_A Interest Ann.	-28.8%	-24.5%	1.4	1.3	1.2	1	3.6	3.8	5.3	7.3	6.6	7.7	4.5	6.2
DEP_A Depr.	27%	17.6%	34.8	34.2	29.5	29.1	16.7	17.7	15.2	11.6	8.7	12.3	15	14.8
PBT_A PBT Ann.	43.7%	25.8%	418.4	391.5	243.3	171.9	132	134.5	124.3	52.7	56	16.7	12	91.6
TAX_A Tax Ann.	46%	28.4%	96.7	90.8	55	38.1	29.2	30.5	26	14.8	12.4	4.2	0.4	20.1
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	43%	25%		300.7	188.3	133.8	102.9	104	98.4	37.9	43.6	12.4	11.6	71.5
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	43%	25%	321.7	300.7	188.3	133.8	102.9	104	98.4	37.9	43.6	12.4	11.6	71.5
NETPCT_A NPM Ann. %	12.6%	6.4%		22.41%	16.03%	15.67%	15.69%	15.79%	16.40%	8.74%	10.28%	4.21%	5.34%	19.96%
EPS_adj_A EPS Adj. latest Ann.	42.1%	24.6%		6.6	4.2	3	2.3	2.3	2.2	0.8	1	0.3	0.3	1.6
result_notes Result Notes				Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

16.1%

2Y CAGR

25.6%

3Y CAGR

26.4%

5Y CAGR

18%

7Y CAGR

18.8%

10Y CAGR

14.7%

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

59.7%

2Y CAGR

49.9%

3Y CAGR

43%

5Y CAGR

25%

7Y CAGR

31.8%

10Y CAGR

15.4%

Net Profit Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

4.9%

2Y CAGR

19.5%

3Y CAGR

21.8%

5Y CAGR

15.9%

7Y CAGR

16%

10Y CAGR

14.9%

Operating Expenses Annual Cr growth is lower than historical averages.

Marksans Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Marksans Pharma Mar-2026 Total Shareholders Fund is Rs 1,652 Cr which is growth of 19.4% YoY.
POSITIVE
Total Assets Marksans Pharma Mar-2026 Total Assets is Rs 1,994 Cr which is growth of 13.6% YoY.

Marksans Pharma Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	14.1%	22.5%	1,652.3	1,383.5	1,222.7	1,111.3	784.7	599.7	505.6	480.6	439	429.9	422.7
EQCAP_A Equity Share Capital Ann.	0%	2.1%	45.3	45.3	45.3	45.3	40.9	40.9	40.9	40.9	40.9	40.9	40.9
TotalShareCapital_A Total Share Capital Ann.	0%	2.1%	45.3	45.3	45.3	45.3	40.9	40.9	40.9	50.9	50.9	51.9	53.4
ReservesAndSurplus_A Reserves Plus Surplus Ann.	14.7%	23.5%	1,607	1,338.2	1,177.4	1,066	743.7	558.8	464.7	429.6	388	378	369.3
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	14.7%	23.5%	1,607	1,338.2	1,177.4	1,066	743.7	558.8	464.7	429.6	388	378	369.3
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	22.8%	5.7%	31.5	26.2	20.9	17	14.4	23.9	24.8	8.4	7.1	6.3	0.3
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	25.7%	15%	17.1	12.2	9.4	8.6	9	8.5	10.8	7	6	5.3	0.3
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	18.7%	-8.1%	8.7	8.3	7	5.2	3.6	13.3	12.5
CL_A Total Current Liabilities Ann. ⌄	12.7%	26.7%	310.3	345.6	272.4	216.5	166.5	94.9	69.4	123	111.2	109.6	111.2
TradePayables_A Trade Payables Ann.	17.4%	23%	180.8	203.5	159.7	111.6	74.5	64.2	56.7	37.2	33.7	20.6	31.4
OtherCurrentLiabilities_A Other Current Liabilities Ann.	7.6%	34.1%	129.1	140.7	110.8	103.6	86.4	29.8	12.2	7.9	10.8	3.8	0.7
ShortTermProvisions_A ST Provisions Ann.	-38.7%	-21.4%	0.3	1.5	2	1.3	0.7	1	0.6	0.6	0.4	11.9	38.5
TL_A Total Capital Plus Liabilities Ann.	14%	22.6%	1,994	1,755.3	1,516	1,344.9	965.6	718.6	599.8	612	557.3	545.8	534.2
FixedAssets_A Fixed Assets Ann. ⌄	39.1%	25.3%	398	383.4	271.6	147.8	135.5	129.1	115.2	102.6	87.9	94.3	97.5
TangibleAssets_A Tangible Assets Ann.	41.1%	26%	396.2	380.9	268.5	140.9	131.9	124.8	110.4	97.2	87.9	91.9	90.3
IntangibleAssets_A Intangible Assets Ann.	-16.6%	-15.6%	1.8	2.5	3.1	3.1	3.7	4.2	4.8	5.4	0	2	7.2
CapitalWorkInProgress_A Capital Work In Progress Ann.	-	-				3.9						0.4
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	16.7%	13.2%	685	673.1	568.3	431.1	375.8	369.3	355.7	340	324.8	329.2	330.2
NonCurrentInvestments_A Non Current Investments Ann.	0.2%	2.5%	267.2	265.8	265.8	265.8	236.1	236.1	236.1	236.1	236.1	234.3	231.4
DeferredTaxAssets_A Deferred Tax Assets Ann.	-	-
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-	-											1.3
OtherNonCurrentAssets_A Other Non Current Assets Ann.	4.2%	36.4%	19.8	24	31	17.5	4.2	4.2	4.5	1.3	0.8	0.6
CA_A Total Current Assets Ann. ⌄	12.7%	30.3%	1,309.1	1,082.2	947.7	913.8	589.9	349.2	244.1	272	232.5	216.6	204
CurrentInvestments_A Current Investments Ann.	20.5%	-		0.7	27	0.5	0.4
TradeReceivables_A Trade Receivables Ann.	26.8%	33.5%	623.5	549.6	370.2	305.5	246.8	146.8	161.9	177.8	168.9	154.8	133.4
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	0.5%	33.4%	446.8	268.7	312.2	440.3	224.1	105.7	3.4	1.8	0.7	2.6	3.1
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-	-											23.8
OtherCurrentAssets_A Other Current Assets Ann.	10.8%	74.2%	49.7	58	47.5	36.5	14.9	3.1	4.2	22	20.6	30
TA_A Total Assets Ann.	14%	22.6%	1,994	1,755.3	1,516	1,344.9	965.6	718.6	599.8	612	557.3	545.8	534.2
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	31.6%	-28.7%	21.2	23.9	22.1	9.3	114.4	115.1	140.4	30.4	11.1	9.2	9.7
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	-	-
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	0.2%	2.5%	267.2	265.8	265.8	265.8	236.1	236.1	236.1	236.1	236.1	234.3	231.4
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-			27

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

13.6%

2Y CAGR

14.7%

3Y CAGR

14%

5Y CAGR

22.6%

7Y CAGR

18.4%

10Y CAGR

14.1%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

-10.2%

2Y CAGR

6.7%

3Y CAGR

12.7%

5Y CAGR

26.7%

7Y CAGR

14.1%

10Y CAGR

10.8%

Total Current Liabilities Annual Cr is falling faster than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

19.4%

2Y CAGR

16.2%

3Y CAGR

14.1%

5Y CAGR

22.5%

7Y CAGR

19.3%

10Y CAGR

14.6%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Marksans Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Marksans Pharma Mar-2026 Book Value Per Share is 36 Rs which is growth of 19.4% YoY.
POSITIVE
ROE Marksans Pharma Mar-2026 ROE is 18% which is growth of 4.6% YoY.

Marksans Pharma Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	14.2%	19.9%	36.5	30.5	27	24.5	19.2	14.7	12.4	11.5	10.5	10.2	10
ROA_A RoA Ann. %	25.4%	1.9%	15.07%	10.72%	8.82%	7.64%	10.76%	13.69%	6.31%	7.12%	2.22%	2.11%	13.38%
ROE_A ROE Ann. %	25.3%	2.1%	18.19%	13.60%	10.93%	9.25%	13.25%	16.40%	7.49%	9.26%	2.89%	2.75%	17.42%
ROCE_A ROCE Ann. %	24.7%	2.3%	23.33%	17.33%	13.90%	12.02%	17.30%	20.79%	11.31%	12.79%	5.45%	3.76%	23.12%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	11%	5.7%	31.83%	23.32%	23.67%	23.25%	23.69%	24.16%	16.53%	16.80%	12.41%	14.56%	31.43%
PBITMargin_A EBIT Ann. Margin %	12.3%	6.3%	29.28%	20.81%	20.26%	20.70%	21.00%	21.62%	13.84%	14.75%	8.25%	7.61%	27.31%
PBTMargin_A PBT Ann. Margin %	13.1%	7.1%	29.18%	20.71%	20.14%	20.15%	20.43%	20.73%	12.16%	13.20%	5.65%	5.53%	25.58%
NETPCT_A NPM Ann. %	12.6%	6.4%	22.41%	16.03%	15.67%	15.69%	15.79%	16.40%	8.74%	10.28%	4.21%	5.34%	19.96%
ASETTO_A Asset Turnover Ann. %	5.3%	-4.9%	0.7	0.7	0.6	0.6	0.8	0.9	0.7	0.7	0.5	0.4	0.7
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	0%	2.6%	4.2	3.1	3.5	4.2	3.5	3.7	3.5	2.2	2.1	2	1.8
QuickRatio_A Quick Ratio Ann.	0%	5.9%	3.6	2.5	2.8	3.6	2.9	2.7	2.4	1.6	1.7	1.7	1.4
DividendPayoutNP_A Dividend Payout to NP Ann.	0%	0%	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.1
EarningRetention_A Earning Retention Ann. %	-0.8%	-1.7%	87.95%	85.56%	83.07%	90.12%	90.16%	95.84%	93.50%	95.31%	80.18%	48.80%	91.91%
CashEarningRetention_A Cash Earning Retention Ann. %	-0.9%	-1.5%	89.18%	87.52%	86.09%	91.50%	91.59%	96.40%	95.03%	96.09%	90.02%	77.74%	93.29%
CashEarningRetention_A Cash Earning Retention Ann. %	-0.9%	-1.5%	89.18%	87.52%	86.09%	91.50%	91.59%	96.40%	95.03%	96.09%	90.02%	77.74%	93.29%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	34.3%	28%	6,674.6	9,807.3	6,555.4	2,754.1	1,645.4	1,938.8	565.6	1,102.7	1,371.1	2,011.6	1,941
EVPerNetSales_A EV Per Net Sales Ann.	6%	9.3%	5	8.4	7.7	4.2	2.5	3.2	1.3	2.6	4.7	9.3	5.4
PBV_A Price To Book Value Adjusted	-12.4%	-16.7%	8.39	10.74	11.34	12.48	15.96	20.88	24.77	26.62	29.2	29.9	30.53
EVPerEBITDA_A EV Per EBITDA Ann.	-4.8%	3.1%	15.6	35.8	32.5	18.1	10.6	13.4	7.9	15.5	37.5	64	17.2
MarketCapPerSales_A Market Cap Per Sales Ann.	2.7%	9.3%	5.3	8.6	8.1	4.9	2.8	3.4	1.3	2.4	4.4	8.9	5.3
RetentionRatios_A Retention Ratio Ann. %	-0.8%	-1.7%	87.94%	85.55%	83.06%	90.11%	90.15%	95.83%	93.49%	95.30%	80.17%	48.79%	91.90%
EYield_A Earnings Yield Ann.	-	-	0	0	0	0	0.1	0.1	0.1	0	0	0	0
DEBT_CE_A Total Debt to Total Equity Ann.							0			0.2	0.2	0.2	0.1

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

33.8%

2Y CAGR

29%

3Y CAGR

25.3%

5Y CAGR

2.1%

7Y CAGR

10.1%

10Y CAGR

0.4%

ROE Annual % is growing faster than historical averages.

RoA Ann. %

1Y CHG

40.6%

2Y CAGR

30.7%

3Y CAGR

25.4%

5Y CAGR

1.9%

7Y CAGR

11.3%

10Y CAGR

1.2%

RoA Annual % is growing faster than historical averages.

Current Ratio Ann.

1Y CHG

35.5%

2Y CAGR

9.5%

5Y CAGR

2.6%

7Y CAGR

9.7%

10Y CAGR

8.8%

Current Ratio Annual growth is higher than historical averages.

Marksans Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Marksans Pharma Mar-2026 Cash From Operating Activity is Rs 211 Cr which is growth of 580.5% YoY.
POSITIVE
Net Cash Flow Marksans Pharma Mar-2026 Net Cash Flow is Rs 32 Cr which is growth of 72.1% YoY.

Marksans Pharma Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	59.8%	14.5%	211.1	31	34.1	51.7	51	107.1	118	19.8	15.6	-13.6	64.8
PBT_A PBT Ann.	43.7%	25.8%	391.5	243.3	171.9	132	134.5	124.3	52.7	56	16.7	12	91.6
INT_A Interest Ann.	-28.8%	-24.5%	1.3	1.2	1	3.6	3.8	5.3	7.3	6.6	7.7	4.5	6.2
TAX_A Tax Ann.	46%	28.4%	90.8	55	38.1	29.2	30.5	26	14.8	12.4	4.2	0.4	20.1
CFI_A Cash from Investing Act. Ann.	-	-	-140.3	17.2	-114.2	-194.6	-8.4	8.8	-24.1	-20.2	-7.6	-7.7	-177.3
CFA_A Cash from Financing Act. Ann.	-	-	-39.2	-29.9	-26.2	210	75.9	-13.5	-92.3	1	-10	20.7	-51.8
NCF_A Net Cash Flow Ann. ⌄	-22.2%	-21%	31.6	18.3	-106.4	67.1	118.4	102.4	1.6	0.6	-1.9	-0.6	-164.4
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-9.7%	77.4%	59.7	41.9	148.3	81.2	105.6	3.4	1.1	0.6	2.5	3.1	167.5
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	-14.9%	-2.9%	91.3	60.3	41.9	148.3	224.1	105.7	2.8	1.1	0.6	2.6	3.1

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

581%

2Y CAGR

148.8%

3Y CAGR

59.8%

5Y CAGR

14.5%

7Y CAGR

40.2%

10Y CAGR

12.5%

Cash from Operating Activity Annual growth is higher than historical averages.

Marksans Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

97.42% Gain from 52W Low

Marksans Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Marksans Pharma - Forecaster

Forecaster Analyst Estimates for Marksans Pharma share price target, revenues, EPS, net income and more